Pfizer

Why is Pfizer Ltd. falling/rising?

As of 01-Aug, Pfizer Ltd. is experiencing a rise in its stock price to 4,822.80, driven by positive performance, increased investor participation, and strong financial metrics, although it has slightly underperformed its sector today. The stock shows potential for an upward trend despite concerns about long-term growth and valuation.

As of 01-Aug, Pfizer Ltd. is experiencing a rise in its stock price, currently at 4,822.80, with a change of 23.75 (0.49%) upward. This increase can be attributed to several factors. The stock has shown a positive performance over the past week, gaining 4.44%, and has risen 4.49% over the last five consecutive days. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 4.18% compared to the five-day average.<BR><BR>Despite the stock's recent gains, it is important to note that it has underperformed its sector by 0.25% today. However, the overall moving averages indicate that the stock is performing better than its shorter-term averages (5-day, 20-day, 50-day, and 100-day) while remaining lower than the 200-day moving average. This suggests a potential upward trend in the near term.<BR><BR>The company also boasts high management efficiency, with a return on equity (ROE) of 17.67%, and is net-debt free, which are positive indicators for investors. Recent financial results have shown strong cash and cash equivalents, as well as a high debtors turnover ratio, further supporting the stock's upward movement.<BR><BR>In summary, Pfizer Ltd.'s stock price is rising due to recent gains in performance, increased investor participation, and strong financial metrics, despite some concerns regarding long-term growth and valuation.

Which are the latest news on Pfizer?

Are Pfizer Ltd. latest results good or bad?

Pfizer Ltd.'s latest Q1 FY27 results are generally positive, with a net profit of ₹204.47 crores and record revenue of ₹653.17 crores, reflecting strong operational efficiency. However, concerns about long-term growth persist due to a low revenue CAGR of 2.39% over the past five years.

Pfizer Ltd.'s latest results for Q1 FY27 can be considered good overall. The company reported a net profit of ₹204.47 crores, which reflects a 2.33% increase quarter-on-quarter (QoQ) and a 6.63% increase year-on-year (YoY). Additionally, revenue reached an all-time quarterly high of ₹653.17 crores, marking an 8.31% growth compared to the same quarter last year and a 3.80% sequential improvement.<BR><BR>One of the standout features of this quarter's performance is the operating margin, which reached 37.90%, the highest in the company's history. This indicates strong operational efficiency and effective cost management, even with rising employee costs. The return on equity (ROE) of 18.05% also suggests robust capital efficiency.<BR><BR>However, while the quarterly results show positive growth and strong profitability metrics, there are concerns regarding long-term growth, as the company has experienced a compound annual growth rate (CAGR) of only 2.39% in revenue over the past five years. This raises questions about its ability to capture market share in a competitive pharmaceutical landscape.<BR><BR>In summary, Pfizer's latest results reflect strong operational performance and profitability, but the company faces challenges in sustaining long-term growth.

Should I buy, sell or hold Pfizer Ltd.?

When is the next results date for Pfizer Ltd.?

The next results date for Pfizer Ltd. is 28 July 2026.

The next results date for Pfizer Ltd. is scheduled for 28 July 2026.

What does Pfizer do?

Pfizer Limited is a Small Cap pharmaceutical company in India, involved in manufacturing and marketing drugs, with recent net sales of 629 Cr and a net profit of 200 Cr as of March 2026. Key metrics include a P/E ratio of 27.00 and a dividend yield of 3.64%.

Overview:<BR>Pfizer Limited is engaged in the manufacturing, marketing, trading, and export of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Pfizer Limited has established itself as a pioneer in clinical research in India. The latest quarterly results reported are for March 2026, showcasing the company's ongoing operations.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 629 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 200 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 20,907 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 27.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 3.64% <BR>Debt-Equity: -0.72 <BR>Return on Equity: 18.05% <BR>Price to Book: 4.94 <BR><BR>Contact Details:<BR>Address: The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E Mumbai Maharashtra : 400051 <BR>Phone: 91-22-66932000 <BR>Email: contactus.india@pfizer.com <BR>Website: http://www.pfizerindia.com

How big is Pfizer?

Summary could not be generated.

As of 10th June, Pfizer Ltd. has a market capitalization of 20,907.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Pfizer reported net sales of 2,519.65 Cr and a net profit of 722.43 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period, but specific values for Shareholder's Funds and Total Assets are unavailable.

Who are in the management team of Pfizer?

The management team of Pfizer includes Prajeet Nair (Company Secretary), Uday Khanna and Sunil Lalbhai (Independent Directors), Milind Anil Patil (Executive Director, Finance), Meena Ganesh (Independent Director), Samir Kazi (Executive Director), Pradip P Shah (Chairman, Independent Director), and Meenakshi Nevatia (Managing Director), who collectively guide the company's strategic direction and ensure regulatory compliance.

The management team of Pfizer includes the following individuals:<BR><BR>- **Prajeet Nair**: Company Secretary & Compliance Officer<BR>- **Uday Khanna**: Independent Director<BR>- **Sunil Lalbhai**: Independent Director<BR>- **Milind Anil Patil**: Executive Director (Finance)<BR>- **Meena Ganesh**: Independent Director<BR>- **Samir Kazi**: Executive Director<BR>- **Pradip P Shah**: Chairman & Independent Director<BR>- **Meenakshi Nevatia**: Managing Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Pfizer?

Pfizer's peers include Acutaas Chemical, Sai Life, Piramal Pharma, Neuland Labs, AstraZeneca, ERIS Lifescience, Granules India, OneSource Specialty, and Caplin Point Lab. Acutaas Chemical shows the highest 1-year return at 187.22%, while Pfizer's return is -22.16%.

Peers: The peers of Pfizer are Acutaas Chemical, Sai Life, Piramal Pharma, Neuland Labs., Astrazeneca Phar, ERIS Lifescience, Granules India, OneSource Speci., and Caplin Point Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Acutaas Chemical and Astrazeneca Phar, while Good management risk is found at Neuland Labs., ERIS Lifescience, Granules India, and Caplin Point Lab. Average management risk is present at Sai Life and Piramal Pharma, and Below Average management risk is noted at OneSource Speci. For Growth, Excellent growth is seen at Acutaas Chemical and Sai Life, while Good growth is found at Neuland Labs. and Piramal Pharma. Below Average growth is noted at Pfizer, ERIS Lifescience, Granules India, and Caplin Point Lab, and the rest have Average growth. In terms of Capital Structure, Excellent capital structure is observed at Acutaas Chemical, Neuland Labs., Astrazeneca Phar, Granules India, and Caplin Point Lab, while Good capital structure is found at ERIS Lifescience, and Below Average capital structure is noted at Piramal Pharma and OneSource Speci.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 187.22%, while Piramal Pharma has the lowest at -19.61%. Pfizer's 1-year return is -22.16%, which is lower than Piramal Pharma's. Additionally, the peers with negative six-month returns include Piramal Pharma and ERIS Lifescience.

Is Pfizer technically bullish or bearish?

As of December 1, 2025, Pfizer's technical stance is mildly bearish due to bearish MACD, Bollinger Bands, and KST indicators on weekly and monthly charts, despite a mildly bullish signal from daily moving averages.

As of 1 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance for Pfizer is mildly bearish. Key indicators driving this stance include a bearish MACD on both weekly and monthly time frames, bearish Bollinger Bands across both time frames, and a bearish KST on the weekly chart. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish sentiment in the weekly and monthly indicators. Additionally, the stock has underperformed compared to the Sensex across multiple time frames, further supporting the bearish outlook.

How has been the historical performance of Pfizer?

Pfizer's historical performance shows fluctuating net sales, increasing from 681.70 Cr in 2008 to 772.27 Cr in 2009, but profitability declined, with profit after tax dropping from 299.58 Cr to 137.12 Cr due to rising expenditures. Despite sales growth, the company faced challenges in managing costs, leading to reduced profit margins.

Answer:<BR>The historical performance of Pfizer shows a trend of fluctuating net sales and profits over the years reported.<BR><BR>Breakdown:<BR>Pfizer's net sales increased from 681.70 Cr in November 2008 to 772.27 Cr in November 2009, indicating a positive growth trend. Other operating income also rose slightly from 22.90 Cr in November 2008 to 24.37 Cr in November 2009. Total operating income followed this upward trajectory, reaching 796.64 Cr in November 2009, up from 704.60 Cr the previous year. However, total expenditure increased significantly from 552.36 Cr in November 2008 to 638.47 Cr in November 2009, leading to an operating profit (PBDIT) of 229.22 Cr in November 2009, which was a modest increase from 222.35 Cr in November 2008. The profit before tax saw a notable decline from 419.13 Cr in November 2008 to 210.01 Cr in November 2009, and consequently, profit after tax also decreased from 299.58 Cr to 137.12 Cr in the same period. This resulted in a drop in earnings per share from 100.4 to 45.95. The operating profit margin and profit after tax margin also decreased, reflecting a decline in profitability. Overall, while Pfizer experienced growth in sales, the profitability metrics suggest challenges in managing costs effectively during this period.

Who are the top shareholders of the Pfizer?

The top shareholders of Pfizer include Pfizer East India B V with 39.75%, mutual funds holding 11.59%, individual investors at 12.34%, and Nippon Life India Trustee Ltd as the largest public shareholder with 4.17%. Foreign Institutional Investors (FIIs) hold 2.18% of the shares.

The top shareholders of Pfizer include Pfizer East India B V, which holds the largest share at 39.75%. Other significant shareholders include mutual funds, which collectively hold 11.59% through 24 schemes, and individual investors, who account for 12.34% of the shares. Additionally, Nippon Life India Trustee Ltd is the highest public shareholder with a 4.17% stake. Foreign Institutional Investors (FIIs) hold 2.18% of the shares through 67 different entities.

Is Pfizer overvalued or undervalued?

As of December 12, 2023, Pfizer is considered very expensive and overvalued with a PE ratio of 41.15 and an EV to EBITDA of 32.17, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex in the short term.

As of 12 December 2023, Pfizer's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 41.15, an EV to EBITDA of 32.17, and a PEG ratio of 2.56, all of which are substantially higher than many of its peers.<BR><BR>In comparison, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla stands at a much lower PE of 22.99 and an EV to EBITDA of 15.93, showcasing that Pfizer's valuation metrics are considerably elevated. Additionally, Pfizer's recent stock performance has outpaced the Sensex over the past month and year, with returns of 32.93% and 14.79%, respectively, although it still lags behind the Sensex over longer periods.

Has Pfizer declared dividend?

Yes, Pfizer has declared a dividend of 350%, amounting to 35 per share, with an ex-date of August 21, 2024. The dividend yield is 0.6%, and total returns over various periods have shown positive performance, particularly in the long term.

Pfizer Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 350%<BR>- Amount per share: 35<BR>- Ex-date: 21 Aug 24<BR><BR>Dividend Yield: 0.6%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 9.39%, with no dividend return, resulting in a total return of 9.39%.<BR><BR>Over the past year, the price return was 17.0%, with a dividend return of 0.71%, leading to a total return of 17.71%.<BR><BR>In the 2-year period, the price return was 44.62%, with a dividend return of 1.04%, culminating in a total return of 45.66%.<BR><BR>For the 3-year period, the price return was 36.06%, with a dividend return of 2.55%, resulting in a total return of 38.61%.<BR><BR>In the 4-year period, the price return was 10.34%, with a dividend return of 1.97%, leading to a total return of 12.31%.<BR><BR>Over the last 5 years, the price return was 39.69%, with a dividend return of 2.87%, resulting in a total return of 42.56%.<BR><BR>Overall, Pfizer's recent dividend declaration reflects a significant return to shareholders, and the total returns over various periods indicate a generally positive performance, particularly in the longer term.